Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 4 , Pages 555-571 , December 2007

Inhaled insulin

  • Sabine Arnolds, MD (Director, Clinical Science)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +49 2131 4018 401; Fax: +49 2131 4018 501.
    • ,
  • Tim Heise, MD (Chief Executive officer, Clinical Science)

References 

  1. The Diabetes Control and Complications Trial (DCCT) Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine. 1993;329:977–986
  2. UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  3. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care. 2003;26:917–932
  4. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care. 2006;29:1263–1268
  5. McMahon GT, Arky RA. Inhaled insulin for diabetes mellitus. The New England Journal of Medicine. 2007;356:497–502
  6. FDA News 27.01.2006, Available at http://www.fda.gov/bbs/topics/news/2006/NEW01304.html.
  7. Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clinical Therapeutics. 2004;26:1498–1505
  8. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care. 1997;20:292–298
  9. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28:2673–2679
  10. Zambanini A, Newson RB, Maisey M, et al. Injection related anxiety in insulin-treated diabetes. Diabetes Research and Clinical Practice. 1999;46:239–246
  11. Zambanini A, Feher MD. Needle phobia in type 1 diabetes mellitus. Diabetic Medicine. 1997;14:321–323
  12. Zambanini A, McIntosh CS, Mitchell C, et al. Psychological issues in diabetes. Lancet. 1999;354:74
  13. Mollema ED, Snoek FJ, Heine RJ, et al. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabetes Medicine. 2001;18:671–674
  14. Gale EA. Two cheers for inhaled insulin. Lancet. 2001;357:324–325
  15. Calvert MJ, McManus RJ, Freemantle N. The management of people with type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Diabetic Medicine. 2007;24(Suppl 1):43
  16. American Diabetes Association . Standards of medical care in diabetes-2007. Diabetes Care. 2007;30(Suppl 1):S4–S41
  17. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535–1540
  18. Heise T, Heinemann L. Rapid and long-acting insulin analogues as an approach to improve insulin therapy: an evidence-based medicine assessment. Current Pharmaceutical Design. 2001;7:1303–1325
  19. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17–20
  20. Gänsslen M. Über Inhalation von insulin. Klinische Wochenschrift. 1925;4:71
  21. Saudek CD. Future developments in insulin delivery systems. Diabetes Care. 1993;16(Suppl 3):122–132
  22. Sayani AP, Chien YW. Systemic delivery of peptides and proteins across absorptive mucosae. Critical Reviews in Therapeutic Drug Carrier Systems. 1996;13:85–184
  23. Patton JS. Deep lung delivery of therapeutic proteins. Chemtech. 1997;27:34–38
  24. Patton J. Pulmonary delivery of insulin. Current Medical Research Opinion. 2006;22(Suppl 3):S5–S11
  25. Wall DA. Pulmonary absorption of peptides and proteins. Drug Delivery. 1995;2:1–20
  26. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Advanced Drug Delivery Reviews. 1999;35:235–247
  27. Byron PR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. Journal of Pharmaceutical Sciences. 1986;75:433–438
  28. Kapitza C, Heise T, Fishman RS, et al. Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol. Diabetes Technology & Therapeutics. 2004;6:119–127
  29. Muchmore DB, Gates JR. Inhaled insulin delivery – where are we now?. Diabetes, Obesity and Metabolism. 2006;8:634–642
  30. Wolff RK. Safety of inhaled proteins for therapeutic use. Journal of Aerosol Medicine. 1998;11:197–219
  31. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clinical Pharmacokinetics. 2004;43:781–801
  32. Exubera® SPC, March 2007. Pfizer Ltd, Kent, UK.
  33. Rave KM, Nosek L, de la Pena A, et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care. 2005;28:2400–2405
  34. Valente A, Langer R, Stone HA, et al. Recent advances in the development of an inhaled insulin product. BioDrugs. 2003;17:9–17
  35. Pfützner A, Mann AE, Steiner SS. TechnosphereTM/insulin – a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technology & Therapeutics. 2002;4:589–594
  36. Hermansen K, Ronnemaa T, Petersen AH, et al. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care. 2004;27:162
  37. Hausmann M, Dellweg S, Osborn C, et al. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study. Diabetes, Obesity and Metabolism. 2006;8:574–580
  38. Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin. Diabetic Medicine. 1997;14:63–72
  39. Rave K, Bott S, Heinemann L, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care. 2005;28:1077–1082
  40. Heinemann L, Klappoth W, Rave K, et al. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care. 2000;23:1343–1347
  41. Gelfand RA, Schwartz SL, Horton ML, et al. Pharmacological reproducibility of inhaled human insulin pre-meal dosing in patients with type 2 diabetes mellitus. Diabetes. 1998;47(Suppl 1):A99
  42. Kapitza C, Hompesch M, Scharling B, et al. Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. Diabetes Technology & Therapeutics. 2004;6:466–472
  43. Perera AD, Kapitza C, Nosek L, et al. Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. Diabetes Care. 2002;25:2276–2281
  44. Pfützner A, Heise T, Steiner S, et al. Inhaled technosphere/insulin shows a low variability in metabolic action in type 2 diabetic patients. Diabetes. 2000;49(Suppl 1):A121
  45. Heinemann L, Heise T. Current status of the development of inhaled insulin. British Journal of Diabetes and Vascular Disease. 2004;4:295–301
  46. Kim D, Mudaliar S, Chinnapongse S, et al. Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. Diabetes Care. 2003;26:2842–2847
  47. Berger M, Mühlhauser I. Diabetes care and patient-oriented outcomes. JAMA. 1999;12(281):1676–1678
  48. Thippawong J, Otulana B, Clauson P, et al. Pulmonary insulin administration using the AERx® insulin diabetes system. Diabetes Technology & Therapeutics. 2002;4:499–504
  49. Garg S, Rosenstock J, Silverman BL, et al. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia. 2006;49:891–899
  50. Peyrot M, Rubin RR, Otterbach K. Effect of Technosphere® inhaled insulin on treatment satisfaction, glycemic control and quality of life. Diabetes. 2006;55(Suppl 1):A100
  51. Tack CJJ, Boss AH, Baughman RA, et al. A randomized, double blind, placebo controlled study of the forced titration of prandial Technosphere®/insulin in patients with type 2 diabetes mellitus. Diabetes. 2006;55(Suppl 1):A102
  52. Boss AH, Evans SH, Ren H, et al. Superior post prandial glucose control in patients with type 1 diabetes when using prandial technosphere insulin compared to NovoLog. Diabetologia. 2006;49(Suppl 1):0181
  53. Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet. 2001;357:331–335
  54. Cappelleri JC, Cefalu WT, Rosenstock J, et al. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clinical Therapeutics. 2002;24:552–564
  55. Weiss SR, Cheng SL, Kourides IA, et al. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Archives of Internal Medicine. 2003;163(19):2277–2282
  56. Skyler JS, Weinstock RS, Raskin P, et al. Use of inhaled insulin in a basal/bolus regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care. 2005;28:1630–1635
  57. DeFronzo RA, Bergenstal RM, Cefalu WT, et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care. 2005;28:1922–1928
  58. Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care. 2004;27:2356–2362
  59. Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Annals of Internal Medicine. 2005;143:549–558
  60. Quattrin T, Belanger A, Bohannon NJV, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care. 2004;27:2622–2627
  61. Barnett AH, Dreyer M, Lange P, et al. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with Metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care. 2006;29:1282–1287
  62. Barnett AH, Dreyer M, Lange P, et al. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on Metformin. Diabetes Care. 2006;29:1818–1825
  63. Advisory Committee Briefing Document: Exubera (insulin (rDNA origin) powder for oral inhalation). Available at http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-416B1_01_01-Pfizer-Exubera.pdf, accessed on 14 March 2007.
  64. Skyler JS, Jovanovic L, Klioze S, et al. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care. 2007;30:579–585
  65. Jendle JH, Karlberg BE. Effects of intrapulmonary insulin in patients with non-insulin-dependent diabetes. Scandinavian Journal of Clinical and Laboratory Investigation. 1996;56:555–561
  66. Edgerton DS, Neal DW, Scott M, et al. Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes. 2005;54:1164–1170
  67. Edgerton DS, Cherrington AD, Williams P, et al. Inhalation of human insulin (Exubera) augments the efficiency of muscle glucose uptake in vivo. Diabetes. 2006;55:3604–3610
  68. Cefalu WT. Inhaled insulin: a proof-of-concept study. Annals of Internal Medicine. 2001;134:795
  69. Ceglia L, Lau J, Pittas AG. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Annals of Internal Medicine. 2006;145:665–675
  70. Rosenstock J, Cappelleri JC, Bolinder B, et al. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care. 2004;27:1318–1323
  71. Scherbaum WA. Unlocking the opportunity of tight glycaemic control. Inhaled insulin: Clinical efficacy. Diabetes, Obesity and Metabolism. 2005;7(Suppl 1):S9–S13
  72. Chan NN, Baldeweg S, Tan TM, et al. Inhaled insulin in type 1 diabetes. Lancet. 1979;2001:357
  73. Teeter JG, Riese RJ. Dissociation of lung function changes with humoral immunity during inhaled human insulin therapy. American Journal of Respiratory and Critical Care Medicine. 2006;173:1194–1200
  74. Fineberg SE, Kawabata T, Finco-Kent D, et al. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism. 2005;90:3287–3294
  75. Heise T, Bott S, Tusek C, et al. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin. A prospective randomized pharmacodynamic study. Diabetes. 2005;28:2161–2169
  76. Henry RR, Mudaliar SRD, Howland WC, et al. Inhaled insulin using the AERx insulin diabetes management system in healthy and asthmatic subjects. Diabetes Care. 2003;26:764–769
  77. Fountaine RJ, Milton A, Wei G, et al. Effects of albuterol and fluticasone on inhaled human insulin (Exubera®) pharmacokinetics in patients with mild-to-moderate asthma. Diabetes. 2006;55(Suppl 1):A112
  78. Rave K, De la Pena A, Tibaldi FS, et al. AIR® inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. Diabetes Care. 2007;30(7):1777–1782
  79. McElduff A, Mather LE, Kam PC, et al. Influence of acute respiratory tract infection on the absorption of inhaled insulin using the AERx insulin diabetes amangement system. British Journal of Clinical Pharmacology. 2005;59:546–551
  80. Camus P. Effect of intercurrent respiratory tract infections on inhaled human insulin (Exubera®) therapy: a retrospective pooled analysis of controlled phase 2 and 3 trials. Diabetologia. 2006;49(Suppl 1):616
  81. Nakano M, Gern J, Stone C, et al. Can the human insulin inhalation powder (HIIP) delivery system can be used during an upper respiratory infection (URI)? The effect of URI on the pharmacokinetics (PK) and glucodynamics (GD) of HIIP in healthy subjects. Diabetologia. 2006;49(Suppl 1):617
  82. Himmelmann A, Jendle J, Mellen A, et al. The impact of smoking on inhaled insulin. Diabetes Care. 2003;26:677–682
  83. Becker RHA, Sha S, Frick AD, et al. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care. 2006;29:277–282
  84. Wise S, Chien J, Yeo K, et al. Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly-Dura inhaled insulin system. Diabetic Medicine. 2006;23:510–515
  85. Nathan DM. Counterpoint: no time to inhale: arguments against inhaled insulin in 2007. Diabetes Care. 2007;30:442–443
  86. Von Kriegstein E, von Kriegstein K. Inhaled insulin for diabetes mellitus. The New England Journal of Medicine. 2007;356:2106
  87. National Institute for Health and Clinical Excellence . Inhaled insulin for the treatment of diabetes (types 1 and 2). Available at http://www.nice.org/TA113December 2006;accessed on 14 March 2007
  88. Cook MN, Girman CJ, Stein PP, et al. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care. 2005;28:995–1000
  89. Freemantle N, Blonde L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care. 2005;28:427–428
  90. Freemantle N, Strack TR, the Real World Trialists . Will availability of inhaled human insulin (Exubera®) improve management of type 2 diabetes? The design of the real world trial. Trials. 2006;7:25
  91. Liebl A, Neiss A, Apannheimer A, et al. Kosten des Typ-2 Diabetes in Deutschland. Ergebnisse der Code-2 Studie. Deutsche medizinische Wochenschrift. 2001;126:585–589
  92. Baxter Press Release, Available at http://www.baxter.com/about_baxter/news_room/news_releases/2007/04-20-07-promaxx.html

PII: S1521-690X(07)00059-0

doi: 10.1016/j.beem.2007.07.004

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 4 , Pages 555-571 , December 2007

Article Tools

* Image Usage & Resolution